Breast Cancer Research and Treatment **25**: 287-286, 1993.
© 1993 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 25

Allasia C 203
Andrac L 203

Bailes JS 119
Bar-Deroma R 211
Bastert G 37
Baumann KH 37
Beex LVAM 21,277
Benedict M 175
Benraad ThJ 21
Benson EA 283
Blank EW 265
Bonnier P 203
Borden EC 141
Brooks SA 247
Brown J 283
Brown ML 113

Camplejohn RS 247
Cantell K 265
Ceriani RL 265
Charpin C 203
Chetrite G 29
Collette C 11

Daniell HW 193
Dapunt O 47
Das Gupta TK 65
Daxenbichler G 47
de Graaf PW 257
Delalonde L 29
De La Rosa A 175
de Mulder PHM 277
De Rosa CM 265
Desch CE 97
Devictor B 203
Dombernowsky P 57
Dori DL 211

Engelholm SA 57

Filice A 193
Filmer A 217
Fintor L 113
Flatow U 175
Frittitta L 73

Gatzmeier W 235
Gibson DFC 141
Goldfine I 73
Goldstein D 141
Grasso G 73
Graves JM 65
Gregory W 247
Grutters JC 277

Habif DV Sr 265
Hackenberg R 217
Hart GD 65
Hawighorst T 217
Hermus ARMM 277
Herrstedt J 57
Hillner BE 97

Jain PT 225
Johnson DA 141
Jones M 283
Jordan VC 141

Kaufmann M 37
Kienhuis CBM 21
Kiesel L 37
Kloppenborg PWC 21
Koenders PG 21
Kostenuik P 151

Lane WW 127
Langan-Fahey SM 141
Lavaut M-N 203
Leathem AJC 247
Leone A 175

Maas MJ 11
MacDonald NJ 175
Magarian RA 225
Marth C 47
Mehta RR 65
Merchant TE 257
Müller LC 47
Müller-Holzner E 47
Neugut AI 211

Nia AH 217
Nicolson GL 165

Obertop H 257
Orr FW 151
Ozzello L 265

Papa V 73
Pasqualini JR 29
Pencil SD 165
Pento JT 225
Piana L 203

Rauschecker H 235
Rennert G 211
Robinson E 211
Rosner D 127
Runnebaum B 37

Sanchez-Sweatman OH 151
Sauerbrei W 235
Schapira DV 107
Schauer A 235
Schmoor C 235
Schulz K-D 217
Schumacher M 235
Shay JW 83
Silkaitis A 65
Singh G 151

Smith TJ 97
Steeg PS 175
Stenbygaard LE 57
Svendsen KR 57

Tam E 193
Thomsen JF 57
Toh Y 165
Trischitta V 73

Ummenhofer L 235

van der Tweel I 11
van Noord PAH 11
Vigneri R 73

Wakeling AE 1
Werbin H 83
Wright WE 83

Ziemet AG 47

Breast Cancer Research and Treatment **25**: 289-292, 1993.
© 1993 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 25

adjuvant therapy
  cost-effectiveness in early breast cancer 97-105
age
  prognostic factor in node-negative breast cancer 127-139
aging
  senescence vs. immortalization, hypothesis 83-94
aminohydroxypropylidene bisphosphonate (APD)
  in treatment of hypercalcemia of breast cancer 277-281
androgen receptor
  and action of MPA in ER/PR-negative breast cancer cells 217-224
annexin I
  association with metastasis 165-174
antiestrogens
  cyclopropyl antiestrogen "compound 7a" 225-233
  pure antiestrogens in clinical breast cancer 1-9
  resistance overcome by factors from mouse fibroblasts 29-35
  toremifene and tamoxifen — cross-over trial 57-63
  see also tamoxifen
athymic mice
  see nude mice

bilateral breast cancer
  follow-up procedures and detection of second primaries 211-215
bisphosphonates
  aminohydroxypropylidene bisphosphonate in treatment of hypercalcemia 277-281
bone metastases
  follow-up after APD in treatment of hypercalcemia 277-281
  mechanisms for targeting metastatic cells to bone 151-163
buserelin (GnRH analogue)
  binding sites in clinical breast cancer specimens 37-46

calpactin II
  see annexin I
clinical practice
  payment and coverage issues in oncology 119-126
clinical trials
  and the Medicare fee schedule 119-126
contralateral breast cancer
  follow-up procedures and detection 211-215
cost analysis
  of diagnosis and treatment — mini-symposium 97-126

decision analysis model
  cost-effectiveness of adjuvant therapy 97-105
differential hybridization
  metastasis-associated genes 165-174
differentiation
  and increased nm23 expression in mammary gland 175-187
  comparing components of histologic grade 235-245
  histological, in prognosis 127-139

EF-1α
  association with metastasis 165-174
EGF receptor
  clinical prognostic study 21-27
  immunocytochemical assay and prognostic factors 203-210
endocrine therapy
  MPA action through androgen receptor 217-224
  new pure antiestrogens 1-9
  toremifene / tamoxifen cross-over trial 57-63

epidemiology
selenium and postmenopausal breast cancer risk 11-19
epidermal growth factor
see EGF
estrogen receptor
negative association with EGF receptor 21-27

fibroblasts
conditioned media and breast cancer cell growth factors 29-35
follow-up, postoperative
and detection of second primaries 211-215
cost-effectiveness 107-111

GAP proteins
no association with nm23 metastasis suppression 182
glycosylation
prognostic abnormality detected by HPA lectin binding 247-256
GnRH binding sites
in clinical breast cancer specimens 37-46
gonadotropin-releasing hormone
see GnRH
grading systems
comparing components of histologic grade 235-245
growth factors
insulin receptor sensitivity in human breast cancer 73-82

Helix pomatia lectin
binding as a prognostic factor 247-256
histologic differentiation
prognostic factor in node-negative breast cancer 127-139
histologic grade
pleomorphism as the prognostic component 235-245
hormone therapy
see endocrine therapy
host factors
influence of smoking and obesity on early tumor behavior 193-201

hypercalcemia
follow-up after APD treatment 277-281

ICI 164,384
and effects of conditioned media on T-47D cells 29-35
pure antiestrogen 1-9
ICI 182,780
pure antiestrogen 1-9
image analysis
applied to immunocytochemical assay of EGF receptor 203-210
imaging
MRI in surgical treatment planning 257-264
immortalization
hypothesis involving p53 and telomere end losses 83-94
immunoconjugates
interferon-α/anti-mucin conjugate for treatment 265-276
immunohistochemistry
progesterone receptor assay in paraffin sections 47-55
insulin receptor
structure and function in human breast cancer 73-82
interferon alpha
conjugate with anti-mucin antibody for treatment 265-276
interferon beta
growth suppression with tamoxifen in MCF-7/nude mouse model 141-150

lectin HPA binding
as a prognostic factor 247-256

magnetic resonance imaging (MRI)
in surgical treatment planning 257-264
mammography
and detection of second primaries 211-215
comparison with MRI in surgical treatment planning 257-264
cost-effectiveness study of screening 113-118
Matrigel
in growth of human breast cancers in nude mice 65-71

MCF-7 cells
actions of the cyclopropyl antiestrogen compound 7a 225-233
tamoxifen/interferon-beta synergism in nude mouse model 141-150
MDA-MB-231 cells
effects of factors from mouse fibroblasts 29-35
medical resource allocation
cost-effectiveness of screening, adjuvant therapy, and postoperative surveillance 97-126
medroxyprogesterone acetate (MPA)
action through androgen receptor 217-224
metastasis
associated genes by differential hybridization 165-174
mechanisms and genes — mini-symposium 151-187
nude mouse model for human breast cancers 65-71
suppression by nm23 gene expression 175-187
MFM-223 human breast cancer cells
action of MPA via androgen receptor 217-224
microenvironment
and model for bone metastasis 151-163
mini-symposia
cost analysis of diagnosis and treatment 97-126
metastases, from genome to therapy 151-187
mitogen-activated protein kinases (MAPKs)
ERK2 association with metastasis 165-174
mitotic index
comparing components of histologic grade 235-245
mucin
Mc5 anti-mucin/interferon-α conjugate for treatment 265-276

nm23
and suppression of metastasis 175-187
Nolvadex
see tamoxifen
nucleoside diphosphate kinase
activity of nm23 gene product 175-187
nude mice
model for growth and metastasis of human breast cancers 65-71
tamoxifen/interferon-beta synergism against MCF-7 growth 141-150

obesity
and larger axillary metastases 193-201
off-label drug uses
and the Medicare fee schedule 119-126
osteolysis
and release of growth factors in bone metastasis 151-163

p53
in immortalization model 83-94
paracrine interactions
factors in fibroblast conditioned media 29-35
pleomorphism
the prognostic component of histologic grade 235-245
postoperative follow-up
cost-effectiveness 107-111
progesterone receptor
immunohistochemical assay parameters in paraffin sections 47-55
reduced in metastatic lymph nodes 47-55
progestins
MPA action through androgen receptor 217-224
prognostic factors
EGF receptor 21-27
EGF receptor vs. other factors 203-210
lectin HPA binding and nodal metastases 247-256
Nottingham Index (letter) 283
pleomorphism as the prognostic component of histologic grade 235-245
tumor size, histologic differentiation, and age in node-negative breast cancer 127-139

quality of life
in cost-effectiveness study of adjuvant therapy 97-105

rat mammary carcinoma 13762NF
metastatic sublines and metastasis-associated genes 165-174
Rb
in immortalization model 83-94

recurrence
  cost-effective strategy for detection 107-111
risk groups
  in node-negative breast cancer 127-139

screening
  cost-effectiveness study 113-118
selenium
  and breast cancer risk 11-19
senescence
  control by telomere end losses, hypothesis 83-94
smoking
  and larger axillary metastases 193-201
surveillance
  cost-effective strategy for detecting recurrence 107-111

T-47D cells
  effects of factors from mouse fibroblasts 29-35
tamoxifen
  comparison with new pure antiestrogens 1-9
  cross-over clinical trial with toremifene 57-63
  enhanced growth suppression by interferon-beta in MCF-7/nude mouse model 141-150
  resistance mechanisms 6-7
  see also antiestrogens
telomere ends
  loss in immortalization model 83-94
TGF-β
  and bone metastasis model 151-163
toremifene
  cross-over clinical trial with tamoxifen 57-63
transforming growth factor
  see TGF
tumor size
  prognostic factor in node-negative breast cancer 127-139
tumor suppressor genes
  see nm23, p53, Rb
tyrosine kinase
  insulin sensitivity in human breast cancer 73-82

Walker 256 rat cells
  and model for bone metastasis 151-163

xenografts
  use of Matrigel for human breast cancers in nude mice 65-71